486 related articles for article (PubMed ID: 17368496)
1. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V
Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
[TBL] [Abstract][Full Text] [Related]
2. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
3. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
4. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
5. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.
van der Sluis TM; Vis AN; van Moorselaar RJ; Bui HN; Blankenstein MA; Meuleman EJ; Heijboer AC
BJU Int; 2012 Jan; 109(2):176-82. PubMed ID: 21992222
[TBL] [Abstract][Full Text] [Related]
6. Baldness, benign prostate hyperplasia, prostate cancer and androgen levels.
Faydaci G; Bilal E; Necmettin P; Fatih T; Asuman O; Uğur K
Aging Male; 2008 Dec; 11(4):189-92. PubMed ID: 19172550
[TBL] [Abstract][Full Text] [Related]
7. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.
Titus MA; Schell MJ; Lih FB; Tomer KB; Mohler JL
Clin Cancer Res; 2005 Jul; 11(13):4653-7. PubMed ID: 16000557
[TBL] [Abstract][Full Text] [Related]
8. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
van der Sluis TM; Meuleman EJ; van Moorselaar RJ; Bui HN; Blankenstein MA; Heijboer AC; Vis AN
BJU Int; 2012 Jan; 109(2):183-8. PubMed ID: 21992404
[TBL] [Abstract][Full Text] [Related]
9. Concentration of the endogenous antiandrogen epitestosterone and androgenic C19-steroids in hyperplastic prostatic tissue.
Hill M; Hampl R; Petrík R; Stárka L
Prostate; 1996 Jun; 28(6):347-51. PubMed ID: 8650070
[TBL] [Abstract][Full Text] [Related]
10. Reduced circulating androgen bioactivity in patients with prostate cancer.
Raivio T; Santti H; Schatzl G; Gsur A; Haidinger G; Palvimo JJ; Jänne OA; Madersbacher S
Prostate; 2003 May; 55(3):194-8. PubMed ID: 12692785
[TBL] [Abstract][Full Text] [Related]
11. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
[TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy: influence on serum and urinary androgen levels.
Olsson M; Ekström L; Schulze J; Kjellman A; Akre O; Rane A; Gustafsson O
Prostate; 2010 Feb; 70(2):200-5. PubMed ID: 19760638
[TBL] [Abstract][Full Text] [Related]
13. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study.
de Jong FH; Oishi K; Hayes RB; Bogdanowicz JF; Raatgever JW; van der Maas PJ; Yoshida O; Schroeder FH
Cancer Res; 1991 Jul; 51(13):3445-50. PubMed ID: 1711411
[TBL] [Abstract][Full Text] [Related]
14. Androgens and estrogens in the plasma and prostatic tissue of normal dogs and dogs with benign prostatic hypertrophy.
Lloyd JW; Thomas JA; Mawhinney MG
Invest Urol; 1975 Nov; 13(3):220-22. PubMed ID: 53217
[TBL] [Abstract][Full Text] [Related]
15. Serum resistin levels in benign prostate hyperplasia and non-metastatic prostate cancer: possible role in cancer progression.
Housa D; Vernerova Z; Heracek J; Cechak P; Rosova B; Kuncova J; Haluzik M
Neoplasma; 2008; 55(5):442-6. PubMed ID: 18665756
[TBL] [Abstract][Full Text] [Related]
16. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
[TBL] [Abstract][Full Text] [Related]
17. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
18. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
[TBL] [Abstract][Full Text] [Related]
19. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate.
Krieg M; Bartsch W; Thomsen M; Voigt KD
J Steroid Biochem; 1983 Jul; 19(1A):155-61. PubMed ID: 6193338
[TBL] [Abstract][Full Text] [Related]
20. Hormonal consequences of orchidectomy for carcinoma of the prostate. With special reference to the measurement of free testosterone in saliva and prostatic dihydrotestosterone levels.
Boccon-Gibod L; Laudat MH; Guiban D; Steg A
Eur Urol; 1988; 15(1-2):99-102. PubMed ID: 3215246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
